Study population
cardiogenic shock, CM, acute coronary syndrome, fever
CARDIOGENIC SHOCK, LIVER DAMAGE, CARDIAC INSUFFICIENCY, INFECTIOUS DISEASE, ACUTE CORONARY SYNDROME, MALIGNANT TUMOR, ALLERGY TO CONTRAST MEDIA
This was an interventional prospective, randomized, single-blind, controlled trial, implemented in all consecutive patients (older than 18 years), undergoing coronary angiography or percutaneous coronary intervention in our department between June 2020 and September 2020 and who had already been receiving atorvastatin for at least one week, before admission.We didn’t include in the present study patients with the following criteria: patients admitted because of an acute coronary syndrome in whom a loading dose is mandatory according to guidelines, statin-naïve patients, patients who received a statin other than atorvastatin before the procedure, patients already receiving 80 mg atorvastatin, patients requiring dialysis and those with eGFR less than 15 ml/min/ 1.73 m2, patients who were exposed to a Contrast Medium (CM) within 7 days, patients with an allergy to contrast media, patients with cardiogenic shock or severe cardiac insufficiency (left ventricular ejection fraction LVEF <20%), patients with severe liver damage, malignant tumor, infectious disease, or fever, and those who refused to consent. We also excluded the patients who didn’t return to get control laboratory tests.The regional ethics committee (The Committee of Protection of the Persons in the South of the country: CPP South) approved the study and all participants signed the written informed consent.The protocol of the study was registered on the Pan-African Clinical Registry (PACTR). The registration number of the study is: PACTR202110707328144.